9th Annual Project & Portfolio Management in the Pharmaceutical Industry
Conference - Vienna, Austria
Increasing budget pressures in the pharma industry, the impact of rising R&D costs and multiple challenges in drug development have led pharma companies to pay far greater attention to their portfolio strategies, resource allocation and decision making processes. Over the course of our 2-day event, attendees will discuss criteria for project prioritization, project diversification, specific risk in pharma projects, soft factors that drive risk evaluation and much more.
Reasons to attend:
Find out about the latest trends in PPM
Understand the impact of the dramatic increase of financial constraints in recent years
Analyse the criteria for project prioritization
Find out if project diversification is the key to success in the pharmaceutical industry
Understand the increasing trend of industry and non-industry collaboration and the benefits and risk they entail
Learn about the specific risk in pharmaceutical projects and identify the soft factors that drive risk evaluation
Enhance business innovation to drive business value
Take part in panel discussions exploring PPM tools and techniques applied by small, mid and large pharmaceutical organisations
Hear about Project & Portfolio Management from a generic pharma perspective
(Courtesy of 9th Annual Project & Portfolio Management in the Pharmaceutical Industry, via pharma.flemingeurope.com)
http://pharma.flemingeurope.com/pharma-ppm-conference
October 01, 2013 - October 02, 2013
Vienna, Austria
Contact: Andrea Weber (andrea.weber@flemingeurope.com)
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.